BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 79 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 1.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $7,000 | -12.5% | 2,100 | 0.0% | 0.00% | – |
| Q2 2021 | $8,000 | -89.9% | 2,100 | -89.8% | 0.00% | – |
| Q1 2021 | $79,000 | -17.7% | 20,678 | -2.7% | 0.00% | – |
| Q4 2020 | $96,000 | -63.8% | 21,249 | +35.5% | 0.00% | – |
| Q3 2020 | $265,000 | +73.2% | 15,683 | +15.0% | 0.00% | – |
| Q2 2020 | $153,000 | +920.0% | 13,640 | +286.8% | 0.00% | – |
| Q4 2019 | $15,000 | -84.0% | 3,526 | -88.2% | 0.00% | – |
| Q1 2018 | $94,000 | -75.6% | 29,912 | -69.7% | 0.00% | – |
| Q4 2017 | $386,000 | +310.6% | 98,590 | +330.0% | 0.00% | – |
| Q3 2017 | $94,000 | – | 22,926 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |